tumor dna News
-
Now recruiting: Bioinformatics Scientist
Do you want to help usher in advanced cancer diagnostics and monitoring to improve patient quality of life and survival? SAGA Diagnostics AB is seeking a talented and highly motivated Bioinformatics Scientist with strong interest in advancing our mission to revolutionize cancer diagnostics through proprietary ultrasensitive technologies that measure circulating tumor DNA (ctDNA) in ...
-
SAGAsafe® technology utilized in new study of ESR1 mutations in breast cancer
ESR1 mutations are found in primary breast cancers prior to therapy initiation and are associated to worse relapse-free and overall survival. These results were reported today by a group of researchers from Lund University and Skåne University Hospital in a new studied published in JNCI Cancer Spectrum. The estrogen receptor alpha is one of the most important breast cancer biomarkers. It ...
-
IMBDx to Attend Bio Health Worldwide Online 2020
IMB Dx is attending the ‘Bio Health Worldwide Online 2020’ exhibit sponsored by KOTRA and the South Korean Ministry of Trade, Industry and Energy which will be held for 12 days beginning October 19th, 2020. Over 500 companies in the fields of biotechnology, pharmaceutical, medical device, healthcare, dietary supplements, and protective supplies, as well as over 1,000 potential buyers ...
By IMB Dx, Inc.
-
Guardant Health to Present Data Highlighting the Clinical Utility of Its Liquid Biopsy Tests in Gastrointestinal Cancers at ASCO GI Cancers Symposium
New Guardant Reveal™ data from interim analysis of COSMOS-CRC-01 demonstrates high performance for recurrence detection in early-stage colorectal cancer REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will present data highlighting the clinical utility of its liquid biopsy tests in the treatment and ...
-
BillionToOne launches oncology liquid biopsy products for research use & announces clinical research collaboration with UCSD
BillionToOne, Inc., a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, announces the launch of its first oncology liquid biopsy products, Northstar Select™ and Northstar Response™. The products are currently available for research use with select academic cancer centers. Northstar Select is a comprehensive ...
-
OncoDNA provides strategic support in Radiomics` prospective clinical trial SALMON
THE TWO BELGIAN COMPANIES WILL WORK TOWARDS A BETTER UNDERSTANDING OF NON-SMALL CELL LUNG CANCER BIOLOGY AND CHARACTERIZATION OF THE TUMORS USING AI TECHNOLOGY Radiomics and OncoDNA are pleased to announce that they have entered into a strategic agreement, combining Radiomics’ next-generation AI-based technology to extract quantitative information embedded in medical images with ...
By OncoDNA S.A.
-
The Importance of DNA Sequencing and Cancer Research
In the simplest of terms, DNA, or deoxyribonucleic acid, is the genetic code that determines all the characteristics of a living thing. This double, long chain of molecules called nucleotides tell each cell what proteins to make, giving them the genetic instruction guide for life and its processes. Each cell’s development, reproduction and death are controlled by the ...
-
OncoDNA and Bergonié Institute to test the clinical utility of blood-and tissue-based biomarker tests in oncology
OncoDNA, a genomic and theranostic company specializing in precision medicine, and Bergonié Institute, a non-profit private hospital entirely devoted to fighting cancer, today announced a new clinical trial to evaluate the use of comprehensive biomarker testing and liquid biopsy in 700 patients diagnosed with an advanced metastatic cancer. The Appolo study will recruit patients from 6 ...
By OncoDNA S.A.
-
Thermo Fisher Scientific Announces Oncomine Clinical Research Grant Program Call for Submissions to Support Research in Immuno-oncology
Thermo Fisher Scientific today announced that submissions are now open for the Oncomine Clinical Research Grant program to support clinical research projects in oncology. This grant aims to provide funding for high-quality molecular profiling studies focusing on the impact of immune-based treatments for cancer patients. Through the Oncomine Clinical Research Grant program, Thermo Fisher will ...
-
C2i Genomics Partners with OncoDNA to Bring AI-Powered Liquid Biopsy for Cancer Diagnostics Across Europe
C2i Genomics, a cancer intelligence company, today announced expansion into Europe through a strategic partnership with OncoDNA, a genomic and theranostic company specializing in precision medicine for the treatment of patients with cancer and genetic diseases. With entities based in Belgium, France, Spain and the UK, OncoDNA has built an outstanding network of cancer clinicians-researchers ...
By OncoDNA S.A.
-
Bayer to present latest research across its advancing oncology portfolio at AACR 2023 Annual Meeting
Bayer presents first Phase 1 results from its most advanced clinical Immuno-Oncology program, aryl hydrocarbon receptor (AhR) inhibitor BAY2416964 New preclinical data on Bayer’s DGK zeta inhibitor being featured in oral presentation in New Drugs on the Horizon session New preclinical data on mutEGFR HER2 program, currently in Phase 1, will be presented Bayer progresses novel research ...
By Bayer AG
-
Creative Proteomics Metabolomics Unveils Drug-Resistant Metabolomics Research Service
Metabolomics, a division of Creative Proteomics, is dedicated to providing cutting-edge LC-MS-based metabolomics services for biomedical research institutions as well as biotechnological and pharmaceutical companies. The company launches the drug-resistant metabolomics research service for oncology research and infectious disease studies regarding drug resistance. Drug therapy is one of the ...
-
Calviri Awarded NCI Grant for the Development of a New Blood Test That May Predict Responders to Checkpoint Inhibitor Therapies
Calviri, Inc., a start-up focused on ending deaths from cancer through unconventional approaches to diagnostics and vaccines, was recently awarded a $300,000 Phase I grant through the Small Business Innovation Research Program (SBIR) at the National Cancer Institute (NCI). This one-year grant will support the development of a new test for establishing whether a cancer patient’s tumor has ...
By Calviri
-
First Completion of a Full Treatment Workflow in the First European Hospital-Based BNCT Facility
BOSTON & LJUBLJANA, Slovenia--(BUSINESS WIRE)--Neutron Therapeutics, a targeted radiation therapy company developing a comprehensive solution for Boron Neutron Capture Therapy (BNCT), and Cosylab, the world's leading provider of control systems for the planet's most complex machines, today announced that they have reached their second joint milestone in the clinical commissioning of Neutron ...
-
Rarecells, Inc. announces Appointment of Dr. Neil Gunn as New Director to the Board
Rarecells, Inc. today announced the appointment of Dr. Neil Gunn, a recognized leader and expert in the diagnostic space, as an independent Board Director. “We are delighted to welcome Neil as Board Director. With his broad understanding of diagnostics and the Liquid Biopsy space he is well-positioned to provide valuable perspectives and insight across a broad spectrum of topics, from ...
-
Cannabis Sequencing and New Cancer Research
In 2014, the entire genome of Cannabis stavia L. was sequenced. This news received national attention with eye-catching headlines such as: “Marijuana Genome Sequenced for Health, Not Highs”. Researchers and oncologists took note, not due to the attention-grabbing headlines, but because their focus was to pair the decoded cannabis genome research with sequencing of the ...
-
Interx, Philochem and Scripps Research Announce A Research Collaboration in the Field of DNA-Encoded Chemistry and Tumor Targeting
InterX, Inc., a privately-owned company, Philochem, a wholly owned subsidiary of Philogen S.p.A., a publicly-listed company, and Scripps Research, a non-profit American medical research facility, today announced the signature of a research collaboration to discover new small molecule therapeutics using InterX’s proprietary computational chemical biology software platform and ...
By InterX
-
NIEHS Funds Six Early-Career Researchers For Innovative Science
New grants totaling $3 million will go to six outstanding early-career scientists, bridging a funding gap to independent biomedical research. The National Institute of Environmental Health Sciences (NIEHS), part of the National Institutes of Health, created the award to encourage early stage researchers who want to discover how our environment influences human health. The highly competitive ...
-
FoundationOne®CDx Receives FDA Approval as a Companion Diagnostic for BRAF Inhibitor Therapeutics in Melanoma
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Foundation Medicine, Inc. today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for FoundationOne®CDx to be used as a companion diagnostic for two groups of current and future FDA-approved therapeutics in melanoma, which includes BRAF inhibitor monotherapies targeting BRAFV600E and BRAF/MEK inhibitor combination ...
-
Cellworks Singula TRI Predicts Personalized Treatment Outcomes for Esophageal Adenocarcinoma Patients Beyond Standard Clinical Factors
Cellworks Group, Inc., a world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology, today announced results from the myCare-004 study, which demonstrate that the Cellworks SingulaTM Therapy Response Index (TRI) is highly predictive of Overall Survival (OS), Disease-Free Survival (DFS) and Mandard-tumor regression grade (TRG) for gastroesophageal adenocarcinoma ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you